

Amendments To The Claims

1. (Withdrawn) A method for treating relapsed B-cell lymphoma comprising administering to a patient having relapsed the B-cell lymphoma a therapeutically effective amount of an anti-CD20 antibody.
2. (Withdrawn) The method of Claim 1, wherein said patient was treated previously with an anti-CD20 antibody.
3. (Withdrawn) The method of Claim 1, wherein said patient previously underwent a bone marrow or stem cell transplantation.
4. (Withdrawn) The method of Claim 1, wherein said patient previously underwent radiotherapy.
5. (Withdrawn) The method of Claim 1, wherein said patient previously underwent chemotherapy for said B-cell lymphoma.
6. (Withdrawn) The method of Claim 5, wherein said chemotherapy is selected from the group consisting of CHOP, ICE, Mitozantrone, Cytarabine, DVP, ATRA, Idarubicin, hoelzer chemotherapy regime, La La chemotherapy regime, ABVD, CEOP, 2-CdA, FLAG & IDA with or without subsequent G-CSF treatment), VAD, M & P, C-Weekly, ABCM, MOPP and DHAP.
7. (Currently amended) A method for treating a subject having B-cell lymphoma, which subject is refractory to treatment with a non-radiolabeled ~~has not exhibited appreciable tumor remission or regression after administration of~~ a chimeric anti-CD20 antibody, comprising administering to said patient a radiolabeled anti-CD20 antibody.
8. (Original) The method of Claim 7, wherein said radiolabeled anti-CD20 antibody is administered from about one week to about two years after said administration of said chimeric anti-CD20 antibody.

9. (Original) The method of Claim 8, wherein said radiolabeled anti-CD20 antibody is administered from about one week to about nine months after said administration of said chimeric anti-CD20 antibody.

10. (Withdrawn) The method of Claim 1, wherein said anti-CD20 antibody is a chimeric anti-CD20 antibody.

11. (Withdrawn) The method of Claim 10, wherein said chimeric antibody is C2B8 (Rituximab®).

12. (Withdrawn) A method for treating B-cell lymphoma comprising administerings a synergistic therapeutic combination comprising at least one anti-CD20 antibody and at least one cytokine, wherein the therapeutic effect is better than the additive effects of either therapy administered alone.

13. (Withdrawn) The method of Claim 12, wherein said at least one cytokine is selected from the group consisting of alpha interferon, gamma interferon, IL-2, GM-CSF AND G-CSF.

14. (Withdrawn) The method of Claim 13, wherein said anti-CD20 antibody and said alpha interferon, gamma interferon, IL-2, GM-CSF or G-CSF is administered sequentially, in either order, or in combination.

15. (Withdrawn) The method of Claim 12, wherein said anti-CD20 antibody is a chimeric antibody.

16. (Withdrawn) The method of Claim 15, wherein said chimeric anti-CD20 antibody is C2B8 (Rituximab®).

17. (Withdrawn) A method for treating B-cell lymphoma comprising administering to a patient a therapeutically effective amount of anti-CD20 antibody before, during or subsequent to a chemotherapeutic regimen.

18. (Withdrawn) The method of Claim 17, wherein said chemotherapy regimen is selected from the group consisting of CHOP, ICE, Mitozantrone, Cytarabine, DVP, ATRA, Idarubicin, hoelzer chemotherapy regime, La La chemotherapy regime, ABVD, CEOP, 2-CdA, FLAG & IDA with or without subsequent G-CSF treatment), VAD, M & P, C-Weekly, ABCM, MOPP and DHAP.

19. (Withdrawn) The method of Claim 17, wherein said anti-CD20 antibody is a chimeric antibody.

20. (Withdrawn) The method of Claim 19, wherein said chimeric antibody is C2B8 (Rituximab®).

21. (Withdrawn) A method for treating B-cell lymphoma comprising administering to a patient a therapeutically effective amount of an anti-CD20 antibody before, during or subsequent to a bone marrow or stem cell transplant.

22. (Withdrawn) The method of Claim 21, wherein said anti-CD20 antibody is a chimeric anti-CD20 antibody.

23. (Withdrawn) The method of Claim 22, wherein said chimeric anti-CD20 antibody is C2B8 (Rituximab®).

24. (Withdrawn) A method of reducing residual CD20+ tumor cells in bone marrow or stem cells before or after myeloablative therapy by administering to a patient an anti-CD20 antibody.

25. (Withdrawn) The method of Claim 24, wherein said anti-CD20 antibody is a chimeric anti-CD20 antibody.

26. (Withdrawn) The method of Claim 25, wherein said anti-CD20 antibody is C2B8 (Rituximab®).

27. (Withdrawn) The method of Claim 1, wherein said B-cell lymphoma is selected from the group consisting of low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, chronic lymphocytic leukemia (CLL), high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma and Waldenstrom's Macroglobulinemia.

28. (Withdrawn) The method of Claim 12, wherein said B-cell lymphoma is selected from the group consisting of low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/ follicular NHL, intermediate grade diffuse NHL, chronic lymphocytic leukemia NHL, high grade small non-cleaved cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma and Waldenstrom's Macroglobulinemia.

29. (Withdrawn) The method of Claim 17, wherein said B-cell lymphoma is selected from the group consisting of low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, chronic lymphocytic leukemia NHL, high grade small non-cleaved cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma and Waldenstrom's Macroglobulinemia.

30. (Withdrawn) The method of Claim 21, wherein said B-cell lymphoma is selected from the group consisting of low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, chronic lymphocytic leukemia NHL, high grade small non-cleaved cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma and Waldenstrom's Macroglobulinemia.

31. (Withdrawn) The method of Claim 24, wherein said B-cell lymphoma is selected from the group consisting of low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, chronic lymphocytic leukemia NHL, high grade small non-cleaved cell NHL, bulky

disease NHL, mantle cell lymphoma, AIDS-related lymphoma and Waldenstrom's Macroglobulinemia.

32. (New) The method of claim 7, wherein the non-radiolabeled chimeric anti-CD20 antibody is rituximab.

33. (New) The method of claim 7, wherein the radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.

34. (New) The method of claim 33, wherein the radiolabeled anti-CD20 antibody is 2B8.

35. (New) The method of claim 1, wherein the radiolabeled anti-CD20 antibody is ⁹⁰Y-labeled anti-CD20.

36. (New) The method of claim 1, wherein the radiolabeled anti-CD20 antibody is ¹³¹I-labeled anti-CD20.

37. (New) The method of claim 7, further comprising administering a B cell depleting amount of a non-radiolabeled chimeric anti-CD20 antibody to the subject prior to administration of the radiolabeled anti-CD20 antibody.